The start of 2019 has already seen some major developments in the pharma world. Huge acquisitions between Bristol-Myers Squibb and Celgene, or GSK’s consumer healthcare business merger with Pfizer are just two examples of the changing landscape in pharma. The very real prospect of a ‘no deal’ Brexit is causing consternation for UK pharma firms and the introduction of the Falsified Medicines Directive in February aims to strengthen supply chains across pharma.
Here, editor Reece Armstrong catches up with some of pharma’s leading names to see what else is in store for 2019.